Overall cognitive profiles in patients with GLUT1 Deficiency Syndrome by V. De Giorgis et al.
Brain and Behavior. 2019;e01224.	 	 	 | 	1 of 11
https://doi.org/10.1002/brb3.1224
wileyonlinelibrary.com/journal/brb3
 
Received:	11	July	2018  |  Revised:	13	November	2018  |  Accepted:	5	December	2018
DOI:	10.1002/brb3.1224
O R I G I N A L  R E S E A R C H
Overall cognitive profiles in patients with GLUT1 Deficiency 
Syndrome
Valentina De Giorgis1  |   Silvia Masnada1,2 |   Costanza Varesio1,3 |  
Matteo A. Chiappedi1 |   Martina Zanaboni1 |   Ludovica Pasca1,3 |   Melissa Filippini4 |   
Joyce A. Macasaet5 |   Marialuisa Valente6 |   Cinzia Ferraris7 |   Anna Tagliabue7 |   
Pierangelo Veggiotti8,9
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided the original work is properly cited.
©	2019	The	Authors. Brain and Behavior	published	by	Wiley	Periodicals,	Inc.
1Department	of	Child	Neurology	and	
Psychiatry,	IRCCS	Mondino	Foundation,	
Pavia,	Italy
2Department	of	Brain	and	Behavioral	
Sciences,	University	of	Pavia,	Pavia,	Italy
3Brain	and	Behavior	Department,	University	
of	Pavia,	Pavia,	Italy
4Child	Neurology	Unit,	IRCCS	Istituto	delle	
Scienze	Neurologiche,	Bologna,	Italy
5Department	of	Neurosciences,	Makati	
Medical	Center,	Manila,	Philippines
6Genomic	and	post‐Genomic	Center,	IRCCS	
‘‘C.	Mondino’’	National	Neurological	
Institute,	Pavia,	Italy
7Human	Nutrition	and	Eating	Disorder	
Research	Center,	Department	of	Public	
Health,	Experimental	and	Forensic	Medicine	
University	of	Pavia,	Pavia,	Italy
8Pediatric	Neurology	Unit,	“V.	Buzzi”	
Hospital,	Milan,	Italy
9Biomedical	and	Clinical	Sciences	
Department,	L	Sacco,	University	of	Milan,	
Milan,	Italy
Correspondence
Valentina	De	Giorgis,	Department	of	Child	
Neurology	and	Psychiatry,	IRCCS	Mondino	
Foundation,	Pavia,	Italy
Email:	valentina.degiorgis@mondino.it
Funding information
Italian	Ministry	of	Health;	Ultragenyx	
Pharmaceutical	Inc.
Abstract
Introduction: Glucose	Transporter	Type	I	Deficiency	Syndrome	(GLUT1DS)	classical	
symptoms	are	seizures,	involuntary	movements,	and	cognitive	impairment	but	so	far	
the literature has not devoted much attention to the last.
Methods: In	our	retrospective	study	involving	25	patients	with	established	GLUT1DS	
diagnosis,	we	describe	the	cognitive	impairment	of	these	patients	in	detail	and	their	
response to the ketogenic diet in terms of cognitive improvement.
Results: We outlined a specific cognitive profile where performance skills were more 
affected	than	verbal	ones,	with	prominent	deficiencies	in	visuospatial	and	visuomo‐
tor	abilities.	We	demonstrated	the	efficacy	of	ketogenic	diet	(KD)	on	cognitive	out‐
come,	with	particular	improvement	tin	total	and	verbal	IQ;	we	found	that	timing	of	
KD	introduction	was	inversely	related	to	IQ	outcome:	the	later	the	starting	of	KD,	the	
lower	the	IQ,	more	notable	nonverbal	scale	(verbal	IQ	correlation	coefficient	−0.634,	
p‐value	=	0.015).	We	 found	 a	 significant	 direct	 correlation	between	 cognition	 and	
CSF/blood	 glucose	 ratio	 values:	 the	 higher	 the	 ratio,	 the	 better	 the	 cognitive	 im‐
provement	 in	 response	 to	 diet	 (from	 T0–baseline	 evaluation	 to	 T1	 on	 average	
18	months	after	introduction	of	KD‐:	TIQ	correlation	coefficient	0.592,	p‐value = 0.26; 
VIQ	correlation	coefficient	0.555,	p‐value	=	0.039).	Finally,	we	demonstrated	that	a	
longer duration of treatment is necessary to find an improvement in patients with 
“severely	low	ratio.”
Conclusion: Our	results	were	consistent	with	the	hypothesis	that	timing	of	the	diet	
introduction	is	a	predictive	factor	of	cognitive	outcome	in	these	patients,	confirming	
that	earlier	initiation	of	the	diet	may	prevent	the	onset	of	all	GLUT1DS	symptoms:	
epilepsy,	movement	disorders,	and	cognitive	impairment.
K E Y W O R D S
cognitive	profile,	epilepsy,	GLUT1DS,	ketogenic	diet,	movement	disorder
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1  | INTRODUC TION
Glucose	 Transporter	 Type	 I	 Deficiency	 Syndrome	 (GLUT1DS)	 is	 a	
metabolic	disorder	due	to	mutations	in	SLC2A1	gene	(1p	31.3→35)	
(Shows	et	al.,	1987)	which	encodes	for	a	specific	transporter	of	glu‐
cose	in	the	brain.	Ketogenic	diet	(KD),	which	provides	ketone	bodies	
instead	of	D‐glucose	as	alternative	fuel	for	cerebral	metabolism,	 is	
at	 current	 time	 the	 gold	 standard	 therapy	 for	GLUT1DS	 (Klepper,	
2008).
Since	the	first	description	of	the	disease	by	De	Vivo	et	al.	(1991),	
different	studies	have	 led	to	 identification	of	 “common	manifesta‐
tions”	of	this	disease	(microcephaly,	cognitive	impairment,	epilepsy,	
continuous	movement	disorders,	and	paroxysmal	exercise‐induced	
dyskinesia)	and	“uncommon	manifestations”	(paroxysmal	kinesigenic	
dyskinesia	 [PKD],	 paroxysmal	 nonkinesigenic	 dyskinesia	 [PNKD],	
oculogyric	 crises,	 and	 fatigue)	 that	 suggest	 a	 high	 probability	 of	
GLUT1DS	 as	 a	 clinical	 diagnosis	 (De	 Giorgis,	 Varesio,	 Baldassari,	
Olivotto,	&	Veggiotti,	2016).
Epilepsy	 occurs	 in	 about	 90%	of	 cases	 and	 seizure	 types	 vary	
widely	 as	 follows	 in	 order	 of	 frequency:	 generalized	 tonic‐clonic	
seizures	(GTCs),	absence,	complex	partial,	myoclonic,	drop	attacks,	
tonic,	 simple	 partial,	 infantile	 spasms,	 and	 epileptic	 spasms	 (Pong	
et	al.,	2012).	KD	was	proven	to	have	an	anticonvulsant	property	in	
many	 studies	 (Kass,	Winesett,	 Bessone,	 Turner,	 &	 Kossoff,	 2016;	
Leen	et	al.,	2010;	Pong	et	al.,	2012;	Ramm‐Pettersen	et	al.,	2013)	but	
the	underlying	mechanism	 is	not	 completely	understood	 (Clanton,	
Wu,	 Akabani,	 &	 Aramayo,	 2017;	 Politi,	 Shemer‐Meiri,	 Shuper,	 &	
Aharoni,	2011).
In	 addition	 to	 seizures,	 involuntary	 movements	 are	 common	
symptoms	of	GLUT1DS	(De	Giorgis	et	al.,	2016)	which	also	demon‐
strated	a	positive	response	to	KD,	(Leen	et	al.,	2010;	Veggiotti	et	al.,	
2010),	even	if	improvement	was	less	evident	compared	to	the	effect	
on	seizures.
Regarding	 cognitive	 impairment	 in	 GLUT1DS	 patients,	 several	
reports	describe	a	mild	or	moderate‐severe	mental	disability	(with‐
out	a	clear	definition	of	degree),	 in	most	cases	proportional	to	dis‐
ease's	 severity	 (Hully	 et	al.,	 2015;	 Larsen	 et	al.,	 2015;	 Leen	 et	al.,	
2010;	Tzadok	et	al.,	2014)	(for	an	overview	of	literature	see	Table	1).	
Hully	 et	al.	 (2015)	 observed	 that	 patients	with	myoclonic	 seizures	
have	 a	 higher	 likelihood	 of	 cognitive	 impairment.	 Ito	 et	al.	 (2015)	
found that mental disability was more severe in patients with earlier 
disease	onset;	furthermore,	they	found	a	better	cognitive	outcome	
in	patients	with	missense	mutations,	higher	CSF/blood	glucose	ratio,	
and a later age of disease onset.
On	the	other	hand,	in	literature,	no	specific	cognitive	profiles	of	
GLUT1DS	patients	are	reported,	except	for	a	case	report	by	Ragona	
et	al.	(2014)	who	described	the	natural	evolution	of	cognitive	profile	
of	a	patient	in	a	span	of	6	years	follow‐up	without	KD.	This	patient	
presented	 a	 mild	 cognitive	 decline	 (8	years	 old:	 TIQ	 (total	 intelli‐
gence	quotient):	95,	VIQ	(verbal	intelligence	quotient):	99,	PIQ	(per‐
formance	intelligence	quotient):	92;	at	12	years	old	IQ:	84,	VIQ:	88,	
and	PIQ:	83)	associated	with	an	impairment	on	neuropsychological	
functions	 (attention,	 executive	 functions,	 visuospatial,	 and	 verbal	
memory)	(Ragona	et	al.,	2014).
Efficacy	of	KD	on	cognitive	 functions	has	been	poorly	 investi‐
gated	so	far,	even	if	an	improvement	was	reported	in	terms	of	visuo‐
motor	precision	 (3/6	patients	 in	Ramm‐Pettersen,	Stabell,	Nakken,	
&	Selmer	2014),	alertness/vigilance,	and	motivation	(6/6	patients	in	
Ito,	Oguni,	 Ito,	Oguni,	&	Osawa	2011;	5/13	patients	 in	De	Giorgis	
et	al.	2015),	IQ	performance	(2/6	patients	in	Ramm‐Pettersen	et	al.	
2014),	 both	 expressive	 and	 receptive	 language	 (3/6	 patients	 in	
Ramm‐Pettersen	et	al.,	2014),	and	sensorimotor	speed	(1/6	patients	
in	 Ramm‐Pettersen	 et	al.	 2014).	 Total	 IQ	 improvement	was	 found	
in	1/13	patients	 in	an	 Italian	group	 (De	Giorgis	et	al.,	2015)	and	 in	
4/6	patients	in	a	Japanese	population	(Ito	et	al.,	2011).	Younger	pa‐
tients	demonstrated	the	most	noteworthy	response	on	KD	(Ramm‐
Pettersen	et	al.,	2013).
Duration	of	KD	was	also	mentioned	to	have	an	impact	on	cogni‐
tion,	particularly	with	an	 improvement	of	TIQ.	 In	Ramm‐Pettersen	
et	al.	 2014	 after	 14	months	 of	 KD,	 a	 patient	 gained	 21	 points	 of	
TIQ	 from	 42	 to	 63	 on	Wechsler	 Preschool	 and	 Primary	 Scale	 of	
Intelligence	 (WPPSI	 III)	 (Wechsler,	 2008);	 a	 patient	 in	 De	 Giorgis	
et	al.	2015,	after	2	years	of	diet,	gained	10	points	of	TIQ	from	79	to	
89	on	WISC	III.	Besides	these	rare	reports,	the	cognitive	profile	 in	
GLUT1DS	has	not	been	deeply	 characterized	 so	 far.	Effectiveness	
of the diet on cognition is probably difficult to assess because of the 
presence of other genetic and environmental factors that could be 
involved in the outcome.
The aim of our study was to describe the cognitive profile in 
GLUT1DS	patients,	before	and	after	 the	KD	 introduction,	 in	order	
to define a specific cognitive profile—in terms of trend of specific 
indexes	of	Wechsler	 Intelligence	Scales	 (total,	verbal,	and	non	ver‐
bal)	and	individual	subtests—to	correlate	it	to	GLUT1	phenotype	and	
outcome	after	KD	introduction.
2  | METHODS
2.1 | Patient selection
This	is	a	retrospective	study	involving	25	patients	with	established	
diagnosis	of	GLUT1DS,	aged	3.7–40	years	(mean	13.16),	composed	
of	seven	males	and	18	females.	All	patients	were	regularly	followed	
up	at	Fondazione	Istituto	Neurologico	Nazionale	C.	Mondino	(Pavia,	
Italy)	between	2007	and	2016.	Informed	consent	was	obtained	from	
children's parents and patients. The study was approved by the 
Ethics	Committee	of	our	Institute.
For	each	patient	included	in	the	study,	information	such	as	type	
of	GLUT1	mutation,	 cerebrospinal	 fluid	 (CSF)/blood	 glucose	 ratio,	
type	 of	 seizure,	 type	 of	 movement	 disorder,	 intelligence	 quotient	
(IQ)	[total	(TIQ),	verbal	(VIQ),	and	performance	(PIQ)],	and	response	
to	the	KD	were	collected.	Classical	KD	was	given	in	4:1,	3:1,	or	2:1	
ratio	 (grams	 of	 fat:	 carbohydrates	 plus	 proteins)	 in	 order	 to	 ob‐
tain	beta‐hydroxybutyrate	 levels	between	2	and	6	mmol/L	 in	each	
patient.
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2.2 | Follow‐up evaluations
Baseline	(T0)	evaluations,	referring	to	the	time	of	GLUT1DS	diagnosis,	
were	available	for	all	25	patients.	Data	were	collected	at	specific	time	
intervals	while	on	KD:	T1,	mean	of	18	months	(range	11–28),	available	
in	14	patients	(five	patients	dropped	out	and	six	patients	did	not	reach	
T1	follow‐up	at	the	time	of	the	study);	T2,	mean	of	36	months	(range	
27–48),	available	in	six	patients	at	the	time	of	the	study.
2.3 | Neuropsychological assessment
Standard	 cognitive	 tests	 measured	 with	 Wechsler	 Intelligence	
Scales	 (Wechsler,	1995,	2012)	 according	 to	 the	age	of	 the	patient	
were	conducted	at	T0,	T1,	and	T2.	Test	administration	was	carried	
out individually by a professional neuropsychologist. Testing was 
divided	 into	 two	 sessions;	 neither	 exceeded	 45	min	 per	 subject	
per	session.	Cognitive	function	was	expressed	as	Total	Intelligence	
Quotient	(TIQ),	Verbal	Intelligence	Quotient	(VIQ),	and	Performance	
Intelligence	Quotient	(PIQ).
Each	subtest	was	analyzed	to	a	have	a	clinical	picture	of	cognitive	
function and its domain.
2.4 | Statistical analyses
Statistical	 analysis	 was	 performed	 using	 SPSS	 statistical	 software	
version	19.0	for	Windows	(SPSS	Inc.,	Chicago,	IL).	After	testing	for	
normal	 distribution	by	mean	of	 the	Kolmogorov–Smirnov	 test,	we	
applied	 nonparametric	 tests.	 Matched	 data	 were	 compared	 with	
Wilcoxon	signed	rank	test,	while	differences	between	groups	were	
assessed	using	the	Mann–Whitney	U‐test.	Values	were	expressed	as	
medians	and	ranges,	while	categorical	variables	were	described	as	
absolute numbers and percentages.
Correlation analysis was then used to identify potential influenc‐
ing	factors	for	IQ	amelioration	in	the	whole	sample.	Nonparametric	
correlation	coefficient	 (Spearman's	Rho)	was	used,	considering	the	
presence of non‐normally distributed variables.
Clinical	variables	analyzed	in	relation	to	cognition	were	the	pres‐
ence	and	type	of	mutation	(missense,	nonsense,	splice	site,	deletion,	
or	frame	shift),	CSF/blood	glucose	ratio,	and	patient's	age	at	the	time	
of	KD	implementation.
2.5 | Ethical statement
We confirm that we have read the Journal's position on issues in‐
volved in ethical publication and affirm that this report is consistent 
with those guidelines.
3  | RESULTS
Our	 sample	 (presented	 in	 detail	 in	 Table	2)	 includes	 25	 patients	
(seven	 males	 and	 18	 females)	 aged	 between	 3.7	 and	 40	years	
(mean	13.16	years),	with	established	diagnosis	of	GLUT1	deficiency	
syndrome.	De	Giorgis	et	al.	 (2015)	previously	 reported	 the	clinical	
data	of	22	patients,	as	presented	in	detail	in	Table	2.
Mutational	findings	were,	in	order	of	frequency,	missense	mutation	
(19	patients),	nonsense	mutation	(two	patients),	deletion	(two	patients),	
frame	shift	mutation	(one	patient),	and	splice	site	mutation	(one	patient).
The	mean	CSF/blood	glucose	ratio	was	0.5	(range	0.34–0.73).
The	majority	of	patients	 (22	of	25)	were	 treated	with	classical	
KD	(4:1,	3:1,	or	2:1	fat	to	nonfat	ratio)	with	an	adequate	compliance	
and	no	serious	side	effects	reported.	Diet	was	introduced	at	a	mean	
age	of	142	months	 (range	22–245	months).	Epilepsy	had	a	positive	
response	to	KD	in	81%	(17	of	21	are	seizure	free)	and	 involuntary	
movements	resolved	in	84%	(16	of	19).
Intelligence	quotient	scores	measured	by	Wechsler	Intelligence	
Scales	were	available	in	all	patients	at	T0	(detailed	description	of	re‐
sults	 in	Supplementary	Table	A).	The	median	scores	were:	 total	 IQ	
of	61	(range:	40–99,	IQR	(interquartile	range):	29),	VIQ	of	66	(range:	
45–118;	IQR:	38),	and	PIQ	of	68	(range:	45–98;	IQR:	32).
Stratification	 of	 patients	 according	 to	 their	 mental	 disability	
showed:
•	 Five	patients	with	normal	TIQ	(mean	95.4;	range	91–99)
•	 Six	patients	with	borderline	TIQ	(mean	78;	range	74–84)
•	 Seven	patients	with	mild	cognitive	impairment	(mean	57.57;	range	
51–66)
•	 Seven	patients	with	moderate‐severe	cognitive	impairment	(mean	
TIQ	45.14;	range	40–50)
A	discrepancy	in	standard	scores	(differences	of	10,	20,	40	points	
between	VIQ	and	PIQ	with	lower	PIQ	score	than	VIQ)	was	present	
in	80%	(20/25)	of	our	subjects.	In	particular	40%	(12	patients)	had	
a	discrepancy	of	<10	points,	20%	(five	patients)	had	a	discrepancy	
>10	points,	and	12%	(three	patients)	had	a	discrepancy	of	>20	points	
(one	patient	had	>40	standard	scores	discrepancy).	Meanwhile,	pa‐
tients	 with	 mild	 cognitive	 impairment	 presented	 at	 the	 opposite,	
having	lower	VIQ	scores	than	PIQ	in	50%	of	the	patients.
Dividing	the	subjects	into	four	groups	according	to	the	TIQ,	we	
found that discrepancy of >10 and >20 points was present uniformly 
in	the	all	groups:	(two	in	normal	TIQ,	two	in	borderline	TIQ;	one	in	
the	mild	cognitive	impairment,	and	three	in	the	moderate	cognitive	
impairment).
Taking	 into	 consideration	 PIQ,	 the	 specific	 subtests(detailed	
description	of	 results	 in	 Supplementary	Table	B)	 that	were	mostly	
affected were Picture Completion with a median standard score of 
5	(range:	1–8;	IQR:	5);	Coding‐Digit	Symbol	with	a	median	standard	
score	4.5	 (range:	1–9;	 IQR:	3);	Picture	Arrangement	with	a	median	
standard	 score	 of	 3	 (range:	 1–9;	 IQR:	 1);	 and	Block	 design	with	 a	
median	standard	score	of	5	(range:	1–9;	IQR:	4.75).
3.1 | KD follow‐up evaluations (T1, 18 months)
Cognitive	 data	 after	 18	months	 of	 follow‐up	 (T1)	 were	 available	
in	 14	 patients.	 Among	 these,	 median	 IQ	 scores	 varied	 with	 an	
improvement	 in	 TIQ	 from	55.5	 (range:	 43–99;	 IQR:	 25.75)	 to	 58	
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(range:	40–97;	IQR:	24),	VIQ	from	64	(range:	45–104;	IQR:	19)	to	
73.5	(range:	45–106;	IQR:	29.75)	and	PIQ	was	substantially	station‐
ary	(from	58.5	[range:	45–98;	IQR:	31]	to	58.5	[range:	45–98;	IQR:	
14.5]).	To	cite,	one	patient	progressed	from	borderline	to	normal	
IQ,	two	patients	slightly	improved	from	mild	cognitive	impairment	
to	borderline	IQ	and	two	patients	improved	significantly	from	mod‐
erate	to	mild	cognitive	impairment	(for	more	details	see	Figure	1).
Correlation	 between	 IQ	 evolution	 (total,	 verbal,	 and	 perfor‐
mance)	 and	 type	of	mutation	was	 attempted,	 but	we	did	 not	 find	
any	 statistically	 significant	 result,	 likewise	 for	 type	 of	 seizure	 and	
movement disorder.
Instead,	 correlation	 between	 CSF/blood	 glucose	 ratio	 and	 IQ	
(total,	verbal	and	performance)	showed	an	improvement	of	TIQ	and	
VIQ	from	T0	to	T1	among	patients	with	higher	CSF/blood	glucose	
ratio	 (TIQ	 correlation	 coefficient	 0.592,	 p‐value	=	0.026;	 VIQ	 cor‐
relation	coefficient	0.555,	p‐value	=	0.039).
On	the	base	of	CSF/blood	glucose	 ratio,	we	classified	patients	
into	three	groups	as	“low	ratio”	group	(>0.40),	“moderately	low	ratio”	
F I G U R E  1   IQ	(Intelligence	Quotient)	scores	at	different	time	points	during	the	follow‐up.	In	green	Normal	IQ,	in	yellow	Borderline	IQ,	
in	orange	Mild	Cognitive	impairment	(ID)	and	in	red	moderate	Cognitive	impairment.	The	arrows	point	out	the	patients	that	had	an	IQ	
amelioration	passing	from	moderate	IQ	to	Mild	IQ,	or	from	Mild	IQ	to	Borderline	IQ,	or	from	Borderline	IQ	to	Normal	IQ
F I G U R E  2  Age	group	according	to	Ketogenic	Diet	(KD)	initiation	and	its	corresponding	WISC‐III	Scores	(Total	Intelligence	Quotient	TIQ,	
Verbal	Intelligence	Quotient	VIQ,	Performance	Intelligence	Quotient	PIQ)	at	T0	(Baseline)	and	at	T1	(18th	month	on	KD).	Early	age	group	
(four	patients),	mean	79	months;	Middle	age	group	(eight	patients),	mean	144	months;	Older	age	group	(three	patients),	mean	233	months	at	
the	age	of	KD	implementation
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group	(0.36–0.39),	and	“severely	low	ratio”	group	(≤	0.35).	IQ	(total,	
verbal	and	performance)	evolution	in	relation	to	CSF/blood	glucose	
ratio was as follows:
•	 in	“severely	low	ratio”	group	TIQ	was	substantially	stationary	with	
worsening	of	VIQ	and	an	improvement	in	PIQ.
•	 in	“moderately	low”	and	“low	ratio”	groups	TIQ	and	VIQ	improved	
over	time	while	PIQ	worsened	(Figure	2).
Timing	of	KD	 introduction	was	 inversely	 related	 to	 IQ	outcome:	
the	older	the	patient,	the	lower	the	IQ,	in	a	more	evident	way	on	verbal	
scale	(VIQ	correlation	coefficient	−0.634,	p‐value	=	0.015).
As	shown	in	Figure	3	patients	who	received	KD	earlier	had	a	better	
IQ	at	T0	and	improved	further.	Dividing	our	patients	into	three	groups	
according	to	 the	age	of	KD	 implementation	we	found	that	younger	
patients	 (mean	6.6	years)	had	better	cognitive	outcome	(in	terms	of	
TIQ,	VIQ,	and	PIQ);	middle	age	group	(mean	12	years)	showed	a	stable	
verbal	 IQ	with	a	worsening	 in	TIQ	and	PIQ;	older	age	group	 (mean	
19.5	years)	acquired	the	lowest	IQ	scores	(TIQ,	VIQ	and	PIQ)	at	T1.
3.2 | KD follow‐up evaluations (36 months, T2)
Six	patients	were	able	to	continue	up	to	36	months	of	KD	treatment	
(T2).	All	demonstrated	an	improvement	in	all	Intelligence	Quotient	do‐
mains	(TIQ,	VIQ,	and	PIQ).	Moreover,	stratifying	the	patients	by	CSF/
blood	glucose	ratio	as	above,	we	found	that	those	with	“severely	low	
ratio”	did	not	show	an	improvement	of	the	IQ	in	the	short‐term	fol‐
low‐up	(T1),	but	a	marked	improvement	was	noted	after	a	long‐term	
(T2)	follow‐up	(Figure	4)	particularly	in	verbal	scores	(VIQ	+28	points).
4  | DISCUSSION
So	 far,	 most	 literature	 data	 focused	 on	 GLUT1DS	 general	 clinical	
profile in both pediatric and adult populations with predominantly 
qualitative description of cognitive function. The majority of reports 
try	to	correlate	KD	response	with	general	outcome	of	al	lGLUT1DS	
symptoms and describe cognitive and behavioral aspects when 
available.
F I G U R E  3  CSF/blood	glucose	ratio	and	its	corresponding	WISC‐III	Scores	at	T0	(baseline)	and	at	T1	(18th	month	of	KD).	Severely	Low	
Ratio	(0.33–0.35)	(three	patients);	Moderately	Low	Ratio	(0.38–0.39)	(four	patients);	Low	Ratio	(0.44–0.56)	(six	patients)
F I G U R E  4  CSF/blood	glucose	ratio	and	its	corresponding	WISC‐III	Scores	at	T0	(baseline),	T1	(18th	month	of	KD)	and	T2	(36th	month	of	
KD).	Severely	Low	Ratio	(0.33–0.35)	(one	patient);	Moderately	Low	Ratio	(0.38–0.39)	(two	patients);	Low	Ratio	(0.44–0.56)	(three	patients)
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Our	experience	clearly	demonstrated	a	peculiar	cognitive	profile	
in	GLUT1DS	patients	where	performance	IQ	was	more	affected	than	
verbal	IQ.	This	result	was	prominent	in	patients	with	normal	and	bor‐
derline	IQ,	where	a	greater	impairment	in	performance	domain	was	
found.
Analyzing	 each	 Wechsler	 Intelligence	 Scales	 (Wechsler,	
1995,	 2012)	 subtest,	 we	 identified	 a	 major	 impairment	 in	 perfor‐
mances	 such	as	Completion	 subtest,	Coding‐Digit	 Symbol,	Picture	
Arrangement,	and	Block	design.	Low	scores	 in	Picture	Completion	
subtest	 reveals	 an	 impairment	 in	 attention	 capacity,	 ability	 to	 ob‐
serve	 details,	 and	 recognize	 specific	 features	 of	 the	 environment.	
Low	 scores	 in	 Coding‐Digit	 Symbol	 imply	 an	 impairment	 in	 visual	
motor	 speed,	 motor	 coordination,	 memory,	 and	 visual	 analysis.	
Deficient	 scores	 in	 Picture	 Arrangement	 pertain	 to	 impairments	
in	 nonverbal	 reasoning,	 sequencing	 skills,	 temporospatial	 analysis,	
mental	 anticipation,	 planning	 capacity,	 speed,	 accuracy,	 and	 grasp	
of	social	cause	and	effect	(also	known	as	social	intelligence).	Lastly,	
deficient	 scores	 in	 Block	Design	 reveal	 impairments	 in	 visual	 per‐
ceptual	skills,	speed,	spatial	problem‐solving,	manipulative	abilities,	
coordination,	and	fluid	intelligence.
Considering	 typical	 clinical	 profile	 of	 GLUT1DS	 patients	 with	
prominent	extrapyramidal	symptoms	such	as	motor	incoordination,	
dysarthria,	fatigue,	continuous	and	paroxystic	movement	disorders,	
we speculate that hindrance in performance skills could be consid‐
erably	influenced	by	this	symptomatology.	Even	if	KD	improved	per‐
formance	and	writing	skills	(Veggiotti	et	al.,	2010),	the	response	to	
KD	on	involuntary	movements	was	not	excellent	(patients	#2	#5).
Taking	into	account	IQ	lower	scores	in	subtests	described	above,	
we	 can	 speculate	 that	GLUT1DS	patients	 have	 a	 typical	 cognitive	
profile with greater difficulties in visuospatial and visuomotor skills. 
Therefore,	according	to	this	evidence,	we	suggest	a	complete	neu‐
ropsychological investigation in order to provide a protocol that bet‐
ter	defines	nonverbal,	visuomotor,	speed	and	accuracy	of	GLUT1DS	
patients.
In	our	study,	we	attempted	to	relate	cognitive	profile	with	clinical	
and	genetic	characteristics	of	GLUT1DS	patients.	We	noticed	that	
there is no direct correlation between type of mutation and cogni‐
tive	impairment,	as	was	noted	by	Ito	et	al.	(2015);	nor	with	type	of	
movement	 disorder	 or	 type	 of	 seizure	 as	 observed	 by	Hully	 et	al.	
(2015).
On	the	other	hand,	we	found	a	significant	direct	correlation	be‐
tween	 IQ	 (particularly	 TIQ	 and	VIQ)	 and	CSF/blood	 glucose	 ratio	
values	in	short‐term	follow‐up	(T1).	Higher	CSF/blood	glucose	ratio	
corresponded	to	a	better	cognitive	improvement	in	response	to	KD	
measured at 18 months. This was clearly demonstrated by dividing 
our	population	into	three	groups	according	to	their	CSF/blood	glu‐
cose	ratio.	In	our	sample,	we	observed	a	better	cognitive	outcome	
in	patients	with	“low”	and	“moderately	low”	ratios	compared	to	“se‐
verely	low	ratio”	group.	The	“severely	low	ratio”	group	obtained	an	
improvement	 in	cognition,	but	a	 longer	duration	of	 treatment	was	
necessary	(T2).
Considering	these	results,	we	can	infer	that	a	longer	duration	of	
KD	treatment	may	be	necessary	to	compensate	greater	CNS	glucose	
transporter	 defect,	 especially	 in	 patients	 with	 severely	 low‐ratio	
values.
In	 a	 longitudinal	 study,	 Alter	 et	al.	 (2015)	 found	 that	 patients	
treated early in infancy had a better long‐term outcome. This group 
hypothesized	that	there	could	be	a	“window	of	vulnerability”	where	
an	increase	in	cerebral	glucose	metabolism,	not	balanced	because	of	
typical	energy	deficit	found	in	GLUT1DS,	causes	damage	to	the	im‐
mature brain. They placed the vulnerability period between first and 
sixth	months	after	birth,	so	they	stated	that	diagnosis	and	treatment	
in this window are critical for improved neurological outcome.
Although	our	population	did	not	include	patients	with	very	early	
diagnosis	and,	thus,	introduction	of	the	KD	in	our	sample	was	at	an	
average	age	of	6	years,	our	results	confirmed	that	the	later	the	age	
of	KD	introduction,	the	worse	the	outcome	of	VIQ	in	both	short	and	
medium term of the diet.
Those patients who started diet before 6 years of age achieved 
a better cognitive outcome; those who started between 6 and 
12	years	had	a	moderate	decline	of	total	IQ	(with	a	stable	VIQ	and	
worse	PIQ).	GLUT1DS	patients	who	started	KD	in	adolescence	suf‐
fered the worst cognitive evolution.
Our	 results	 are	 consistent	 with	 the	 hypothesis	 that	 timing	 of	
KD	introduction	is	a	predictive	factor	for	cognitive	outcome	in	pa‐
tients	 with	 GLUT1DS	 and	 that	 an	 earlier	 introduction	 of	 the	 diet	
may	prevent	not	only	epilepsy	and	movement	disorder	onset	 (pre‐
viously	widely	demonstrated	by	different	studies	(Kass	et	al.,	2016;	
Leen	 et	al.,	 2010;	 Pong	 et	al.,	 2012;	 Ramm‐Pettersen	 et	al.,	 2013;	
Veggiotti	et	al.,	2010)	but	also	cognitive	 impairment.	Furthermore,	
on	the	basis	of	our	experience,	we	can	speculate	that	the	“window	
of	vulnerability”	could	be	expanded	in	the	early	childhood	as	far	as	
cognition is concerned.
Although	duration	of	dietary	 therapy	was	not	clearly	 stated	 in	
GLUT1DS	 therapeutic	 guidelines,	 physicians	 agree	 about	 obvious	
efficacy	 and	 good	 tolerability	 of	 KD	 on	 epilepsy	 and	 involuntary	
movements	in	the	long	term.	So	far,	less	data	are	available	in	litera‐
ture	about	cognition,	but	studies	available	showed	a	better	cognitive	
outcome in patients with earlier diagnosis and early introduction of 
KD	(Ramm‐Pettersen	et	al.,	2013).	Our	data	confirm	that	an	early	KD	
introduction and a good compliance to the diet are predictive also of 
a	better	cognitive	outcome,	and	our	study	confirms	that	prolonged	
treatment	 with	 KD	 is	 needed	 in	 order	 to	 increase	 the	 chance	 of	
achieving at least a partial recovery of neuropsychological deficits. 
Other	possible	environmental	factors	may	have	influenced	the	cog‐
nitive	improvements	described	in	our	patients:	family	care,	speech	
and	other	supportive	therapies,	KD	ratio	and	compliance	to	the	KD;	
probably	KD	with	higher	ratios	could	give	a	more	rapid	and	effective	
response.	In	our	experience,	patients	with	drastic	diets,	carried	out	
for	a	long	period	had	higher	noncompliance	issues	and	dropouts.	For	
this	reason,	all	our	patients	were	prescribed	a	classical	KD	with	vari‐
able ratios—but more frequently 3:1 or 2:1—with the aim of main‐
taining	beta‐hydroxybutyrate	levels	between	2	and	6	mmol/L	which	
have guaranteed the compliance to all of the patients recruited in 
our	study	and	allowed	a	good	efficacy	response	in	terms	of	epilepsy,	
movement	disorder,	and	cognition.
10 of 11  |     DE GIORGIS Et al.
Considering	 that	 our	 results	 refer	 to	 a	 group	of	GLUT1DS	pa‐
tients	with	heterogeneous	socio‐economic	levels	(parents’	education	
level,	parents’	careers	and	salary,	parents’	health)	which	influenced	
compliance	to	KD	and	cognitive	outcome,	it	cannot	be	excluded	that	
other environmental or unknown genetic factors could influence 
both initial cognitive competence and outcome after treatment. 
Definitely,	other	studies	involving	a	larger	population	are	needed	to	
confirm	our	findings,	characterize	in	more	detail	GLUT1DS	patients’	
cognitive	profile	and	clearly	assess	response	to	KD	therapy.
Based	 on	 our	 cognitive	 results,	 we	 suggest	 applying	 to	 all	
GLUT1DS	 patients	 a	 complete	 neuropsychological	 investigation,	
studying in detail the visuospatial and visuomotor skills which were 
more compromised in our sample.
5  | LIMITATIONS
Future	studies,	which	include	a	larger	population,	a	longer	follow‐up	
and	higher	statistical	power,	are	necessary	in	order	to	obtain	a	better	
explanation	of	our	results.
A	relevant	limitation	of	our	study	was	the	age	of	introduction	of	
the	KD	conditioned	by	 late	diagnosis,	 so	our	data	could	not	accu‐
rately	outline	the	“window	of	vulnerability.”
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